Daniel P. Petrylak
- Oncology top 0.05%
- Pulmonary and Respiratory Medicine top 0.05%
- Surgery top 0.1%
- Molecular Biology top 1%
- Cancer Research top 0.2%
- Co-authors
- Joaquim BellmuntMaha HussainMitchell C. BensonNicholas J. VogelzangYohann LoriotE. David CrawfordEric J. SmallPrimo N. Lara
- Topics
- Prostate Cancer Treatment and Research (234 papers)Bladder and Urothelial Cancer Treatments (224 papers)Cancer Immunotherapy and Biomarkers (162 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Daniel P. Petrylak
510 papers receiving 22.7k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 11.1k
- Pulmonary and Respiratory Medicine 10.7k
- Surgery 7.5k
- Molecular Biology 4.9k
- Cancer Research 3.4k
Countries citing papers authored by Daniel P. Petrylak
This map shows the geographic impact of Daniel P. Petrylak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Petrylak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Petrylak more than expected).
Fields of papers citing papers by Daniel P. Petrylak
This network shows the impact of papers produced by Daniel P. Petrylak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Petrylak. The network helps show where Daniel P. Petrylak may publish in the future.
Co-authorship network of co-authors of Daniel P. Petrylak
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Petrylak. A scholar is included among the top collaborators of Daniel P. Petrylak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Petrylak. Daniel P. Petrylak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 2 | |
| 5 | 3 | |
| 6 | 10 | |
| 7 | 14 | |
| 8 | 2 | |
| 9 | 3 | |
| 10 | Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancerbreakdown → | 163 |
| 11 | 54 | |
| 12 | 33 | |
| 13 | 33 | |
| 14 | 74 | |
| 15 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinomabreakdown → | 223 |
| 16 | 3 | |
| 17 | 26 | |
| 18 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinomabreakdown → | 2374 |
| 19 | 186 | |
| 20 | 19 |
About Daniel P. Petrylak
Daniel P. Petrylak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery, having authored 529 papers that have together received 23.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (234 papers), Bladder and Urothelial Cancer Treatments (224 papers) and Cancer Immunotherapy and Biomarkers (162 papers). The work is most often cited by research in Oncology (11.1k citations), Pulmonary and Respiratory Medicine (10.7k citations) and Cancer Research (3.4k citations). Daniel P. Petrylak has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Joaquim Bellmunt, Maha Hussain, Mitchell C. Benson, Nicholas J. Vogelzang, Yohann Loriot, E. David Crawford, Eric J. Small, Primo N. Lara, Catherine M. Tangen and Patrick A. Burch. Their work appears in journals such as Nature, New England Journal of Medicine and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.